The Pink Sheet, a leading publication providing expert analysis of the biopharma industry, covered the Foundation’s recent “Business Opportunities in NF” satellite meeting as part of the 2014 NF Conference in Washington, DC. They’ve published two in-depth articles on the Foundation’s strategic plan.
The first article: Neurofibromatosis Could Drive Cancer Indications, Advocacy Group Says, is focused on the Foundation’s partnership model that brings together researchers from across scientific research disciplines, beyond just NF.
The second article: A Shift In Thinking: FDA Moves Toward Easier Neurofibromatosis Endpoints, focuses on efforts towards a faster path to drug approvals for NF.
The above two articles, plus our recent coverage in BioWorld, show that the biotech and pharma industries are taking notice of neurofibromatosis, and the work of the Children’s Tumor Foundation leadership in driving the agenda to a cure for NF.
